Lenalidomide - CAS 191732-72-6
Catalog number:
191732-72-6
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C13H13N3O3
Molecular Weight:
259.26
COA:
Inquire
Targets:
TNF-alpha
Description:
Lenalidomide strongly induces IL-2 and sIL-2R production. Lenalidomide-induced tyrosine phosphorylation of CD28 on T cells is followed by a down-stream activation of NF-κB.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
CC-5013
MSDS:
Inquire
1.Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Vel N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.
BACKGROUND: Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma.
2.A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome.
Cherian MA1, Tibes R2, Gao F3, Fletcher T1, Fiala M1, Uy GL1, Westervelt P1, Jacoby MA1, Cashen AF1, Stockerl-Goldstein K1, DiPersio JF1, Vij R1. Leuk Lymphoma. 2016 Apr 27:1-6. [Epub ahead of print]
Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by bone marrow failure which frequently progress to acute myeloid leukemia. Patients who fail to respond to, or progress on first-line DNA hypomethylating agents (HMA) have a poor prognosis. Conventionally dosed lenalidomide has activity in 5q-MDS. In other subtypes, it may reduce RBC transfusion requirements but does not result in cytogenetic responses. We previously reported that high-dose lenalidomide induction (50 mg/day) results in complete remissions in a high fraction of patients. We, therefore, conducted a Phase 2 trial of the same regimen in MDS refractory to HMA. Marrow complete remissions were seen in 33% of patients and hematological improvement in 8% of patients. Significant infections complicated more than 50% of cases. Future trials to explore alternative dosing schedules of high-dose lenalidomide to increase efficacy while decreasing toxicity are warranted.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related TNF-alpha Products


CAS 1420071-30-2 Bioymifi

Bioymifi
(CAS: 1420071-30-2)

Bioymifi is a potent and selective death receptor 5 (DR5) activator. Bioymifi works by mimicking the ability of TRAIL to stimulate clustering of DR5, triggering...

CAS 852391-15-2 Necrostatin 2 racemate

Necrostatin 2 racemate
(CAS: 852391-15-2)

Necrostatin 2 racemate is the racemate of Necrostatin, which is a potent necroptosis inhibitor.

CAS 20931-37-7 β-mangostin

β-mangostin
(CAS: 20931-37-7)

Beta-mangostin, a natural product extracted from the fruits of Garcinia mangostana, can reduced the levels of TNF-α and IL-1β in peritoneal fluid.

CAS 847871-99-2 Lenalidomide hemihydrate

Lenalidomide hemihydrate
(CAS: 847871-99-2)

Lenalidomide is a TNF-α secretion inhibitor.

CAS 84088-42-6 Roquinimex

Roquinimex
(CAS: 84088-42-6)

Roquinimex, also known as LS 2616 and FCF89 (brande name: Linomide), is a quinoline-3-carboxamide with potential antineoplastic activity. Roquinimex inhibits en...

CAS 186763-78-0 Ginsenoside Rg5

Ginsenoside Rg5
(CAS: 186763-78-0)

Ginsenoside Rg5, a main constituent isolated from red ginseng, exhibits anti-inflammatory property as in LPS-stimulated alveolar macrophages it inhibited the ex...

CAS 852391-20-9 Necrostatin 2 S enantiomer

Necrostatin 2 S enantiomer
(CAS: 852391-20-9)

Necrostatin 2 S enantiomer is the S enantiomer of Necrostatin, which is a potent necroptosis inhibitor.

CAS 212609-68-2 GW-3333

GW-3333
(CAS: 212609-68-2)

GW-3333 is a dual inhibitors of tumor necrosis factor-alpha (TNF)-Converting Enzyme (TACE) and matrix metalloproteinases.

CAS 4311-88-0 Necrostatin-1

Necrostatin-1
(CAS: 4311-88-0)

Necrostatin-1 is a specific RIP1 inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM.

BMS561392
(CAS: 611227-74-8)

BMS561392 is a tumor necrosis factor-alpha (TNF alpha) converting enzyme inhibitor. It has the potential treatment of diseases characterized by overproduction o...

CAS 192819-27-5 CDC801

CDC801
(CAS: 192819-27-5)

A potent, orally active and dual inhibitor of phosphodiesterase 4 (PDE4) (IC50= 1.1 μM) and tumor necrosis factor-α (TNF-α) (IC50= 2.5 μM).

CAS 13419-46-0 DCVC

DCVC
(CAS: 13419-46-0)

DCVC has been found to influence sort of cytokines release stimulated by pathogen.

CAS 5786-54-9 Hispidol

Hispidol
(CAS: 5786-54-9)

Hispidol ((Z)-Hispidol) inhibits TNF-α induced adhesion of monocytes to colon epithelial cells (IC50= 0.50 µM) and is a potential therapeutic for inflammatory b...

CAS 191732-72-6 Lenalidomide

Lenalidomide
(CAS: 191732-72-6)

Lenalidomide strongly induces IL-2 and sIL-2R production. Lenalidomide-induced tyrosine phosphorylation of CD28 on T cells is followed by a down-stream activati...

CAS 852391-19-6 Necrostatin 2

Necrostatin 2
(CAS: 852391-19-6)

Necrostatin 2 is a potent necroptosis inhibitor. It is a potent in vitro necroptosis inhibitors and is also efficacious in an animal model of ischemic stroke.

CAS 19171-19-8 Pomalidomide

Pomalidomide
(CAS: 19171-19-8)

Pomalidomide inhibits lipopolysaccharide (LPS) stimulated TNF-alpha release in human PBMC and in human whole blood with IC50 values of 13 nM and 25 nM, respecti...

CAS 1243329-97-6 Lenalidomide hydrochloride

Lenalidomide hydrochloride
(CAS: 1243329-97-6)

Lenalidomideis a derivative of thalidomide introduced in 2004. Lenalidomide (Revlimid, CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM.

Chemical Structure

CAS 191732-72-6 Lenalidomide

Quick Inquiry

Verification code

Featured Items